(Q38639091)

5 September 2017

title

Development of a recombinant, chimeric tetravalent dengue vaccine candidate (English)

1 reference

5 September 2017

0 references

1

Jorge E Osorio

1 reference

5 September 2017

author name string

Charalambos D Partidos

series ordinal

2

1 reference

5 September 2017

Derek Wallace

series ordinal

3

1 reference

5 September 2017

Dan T Stinchcomb

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

13 November 2015

1 reference

5 September 2017

1 reference

5 September 2017

volume

33

1 reference

5 September 2017

issue

50

1 reference

5 September 2017

page(s)

7112-7120

1 reference

Dengue: a continuing global threat

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

The global distribution and burden of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Dengue virus-mosquito interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Refining the global spatial limits of dengue virus transmission by evidence-based consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Clinical implications and treatment of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Quality of life of dengue patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Quality of life among adults with confirmed dengue in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Antibody response to dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

T-cell immunity to infection with dengue virus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

A Protective Role for Dengue Virus-Specific CD8+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Efficacy of a tetravalent dengue vaccine in children in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Epidemiology of dengue disease in Malaysia (2000-2012): a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5' untranslated region and amino acid substitutions in nonstructural proteins 1 and 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Animal models of dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

A Dengue Virus Type 4 Model of Disseminated Lethal Infection in AG129 Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Inflammatory and innate immune responses in dengue infection: protection versus disease induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

New mouse model for dengue virus vaccine testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.022

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.11.022

1 reference

5 September 2017

1 reference